Stock Analysis, Dividends, Split History

ATROB / Astronics Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price32.04
Volume0.00
Market Cap ($M)690.26
Enterprise Value ($M)944.99
Book Value ($M)351.29
Book Value / Share16.31
Price / Book1.96
NCAV ($M)-59.64
NCAV / Share-2.77
Price / NCAV-11.57
Share Statistics
Common Shares Outstanding 21,273,979
Common Shares Outstanding2 6,792,785
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.03
Return on Assets (ROA)0.03
Return on Equity (ROE)0.06
Balance Sheet (mrq) ($M)
Assets764.42
Liabilities413.13
Quick Ratio1.68
Current Ratio3.05
Income Statement (mra) ($M)
Sales Revenue Goods Net624,464,000.00
Operating Income30.36
Net Income19.68
Earnings Per Share Basic0.69
Earnings Per Share Diluted0.67
Cash Flow Statement (mra) ($M)
Cash From Operations37.78
Cash from Investing-129.56
Cash from Financing37.78
Identifiers and Descriptors
CUSIP046433207
Central Index Key (CIK)8063

Split History

Stock splits are used by Astronics Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related News Stories

7 Market-Beating Stocks to Buy to Weather a Trade War

2h investorplace
Next week, the trade war with China version 2.0 begins. The U.S. will slap tariffs on $200 billion worth of Chinese goods headed to the U.S. How will this affect which stocks to buy? Well, this has hardly rattled the broad markets — as a matter of fact, that they’re acting as they do when they get any good news. Realistic news that the trade war is having an effect is punished for merely being uttered. (8-0)

Astronics Corporation (ATRO) CEO Pete Gundermann on Q2 2018 Results - Earnings Call Transcript

2018-08-03 seekingalpha
Greetings and welcome to Astronics Corporation Second Quarter 2018 Financial Results Conference. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

Astronics: A Stock Worth Avoiding

2018-06-25 seekingalpha
Astronics Corporation is a supplier of advanced, high-performance avionics and testing systems, with revenues of about $650 million. (67-1)

Moving Average Crossover Alert: Astronics Corporation (ATRO)

2018-06-01 zacks
Astronics Corporation (ATRO - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for ATRO broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness. (15-0)

New Strong Sell Stocks for May 14th

2018-05-14 zacks
Adient plc (ADNT - Free Report) is a designer and manufacturer of seating systems and components. The Zacks Consensus Estimate for its current year earnings has been revised 4.8% downward over the last 60 days. (47-0)

Astronics Corporation's (ATRO) CEO Peter Gundermann on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Greetings and welcome to Astronics Corporation's First Quarter 2018 Financial Results. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded. (13-0)

New Strong Sell Stocks for April 18th

2018-04-18 zacks
Acorda Therapeutics, Inc. (ACOR - Free Report) is a developer of therapies for neurological disorders. The Zacks Consensus Estimate for its current year earnings has been revised 93.2% downward over the last 60 days. (43-0)

CUSIP: 046433207